抗抑郁药,催眠药和抗焦虑药对复合人体乙胆酶活性的抑制作用
Keisuke Obara1, Haruka Mori1, Suzune Ihara1
1Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University.
Biological & pharmaceutical bulletin
|January 31, 2024
概括
某些精神药物,包括抗抑郁药,可以抑制乙胆酶 (AChE) 活性,可能减缓阿尔茨海默氏病 (AD) 的进展. 在临床剂量下,nefazodone显示出有前途的ACHE抑制,这表明AD患者的双重益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 经常与痴呆症 (BPSD) 的行为和心理症状有关.
- 心理药物如抗抑郁药,催眠药和抗焦虑药通常用于管理BPSD.
- 这些药物的子集可能具有乙胆酶 (AChE) 抑制性质,通过调节大脑乙胆水平,可能会影响AD的进展.
研究的目的:
- 调查常见处方精神药物抑制人类乙胆酶 (AChE) 活性的潜力.
- 为了确定表现出显著的ACHE抑制的特定抗抑郁药,催眠药和焦虑缓解药.
- 评估ACHE抑制精神药物的治疗潜力,以管理阿尔茨海默病的BPSD和认知衰退.
主要方法:
- 选31种抗抑郁药,21种催眠药和12种焦虑缓解药,以检测它们对复合人类ACHE (rhAChE) 活性的抑制作用.
- 确定显著的ACHE抑制所需的药物度 (在10-4M时≥20%).
- 计算强效抑制剂的pIC50值,并评估它们在临床相关度下的抑制活性.
主要成果:
- 九种抗抑郁药,两种催眠药和一种抗焦虑药显示出显著的rhAChE抑制 (≥20%在10−4M).
- 布罗西佐拉姆表现出最强的抑制 (pIC50 = 4.57 ± 0.02),其次是其他确定的药物,pIC50值<4.
- 只有nefazodone在临床剂量可达到的血液度范围内显示出显著的rhAChE抑制.
结论:
- 几种精神药物具有ACHE抑制性质,这表明在管理AD症状方面存在潜在的双重作用机制.
- 纳法佐因其在临床相关度下抑制rhAChE活性的能力而脱而出,为BPSD和AD认知进展提供了潜在的益处.
- 需要进一步的临床研究来确认nefazodone和其他在阿尔茨海默病患者中确定的ACHE抑制精神药物的治疗疗效.
更多相关视频
10:48Probing Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices via Laser Flash Photolysis of Photoactivatable Nicotine
Published on: January 25, 2019
9.3K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.7K
相关概念视频
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
675
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
675
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
567
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
567
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
982
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
982
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.2K